VEGFA and small cell lung carcinoma: Although VEGF is expressed in SCLC, the anti-VEGF antibody bevacizumab yielded conflicting or disappointing results, with ORRs of 58.0-91.9 and median PFS of 4.7–7.8 months [13, 24–26], without differences compared with the control arm [13].